Pharmacovigilance of esketamine nasal spray: an analysis of the FDA adverse event reporting system database

• Главные авторы: Ruixue Liu (Автор), Chunxiao Liu (Автор), Dianwei Feng (Автор), Tongxin Guo (Автор), Ying Wang (Автор)
• Формат: ‌
• Опубликовано: Frontiers Media S.A., 2024-06-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Esketamine nasal spray (ESK-NS) is a new drug for treatment-resistant depression, and we aimed to detect and characterize the adverse events (AEs) of ESK-NS using the Food and Drug Administration (FDA) adverse event reporting system (FAERS) database between 2019 Q1 and 2023 Q4. Reporting odds ratio...